FAM83A and FAM83B: Candidate Oncogenes and TKI Resistance Mediators

Overview

Journal J Clin Invest

Specialty General Medicine

Date 2012 Aug 14

PMID 22886299

Citations 29

Authors

Steven Grant

Affiliations

Soon will be listed here.

Abstract

The growth and survival of tumor cells can depend upon the expression of a single oncogene, and therapeutically targeting this oncogene addiction has already proven to be an effective approach in fighting cancer. However, it is also clear that cancer cells can adapt and become resistant to therapy through compensatory activation of downstream pathways that relieve the cell of its addicted phenotype. In this issue of the JCI, two groups--Lee et al. and Cipriano et al.--identify two related candidate oncogenes that might both contribute to therapeutic resistance to tyrosine kinase inhibitors (TKIs). If validated, this information could help to identify new targets for therapeutic interventions in breast cancer and possibly other cancers and may also assist in the development of strategies designed to overcome resistance to currently available TKIs.

Citing Articles

Diagnostic value of immune-related biomarker FAM83A in differentiating malignant from benign pleural effusion in lung adenocarcinoma.

Liu H, Yao J, Liu Y, Wu L, Tan Z, Hu J Discov Oncol. 2024; 15(1):242.

PMID: 38914812 PMC: 11196556. DOI: 10.1007/s12672-024-01109-7.

FAM83B promotes cell proliferation via regulating the expression of CDK4/CDK6/CCND1 complex in laryngeal squamous cell carcinoma.

Hu X, Zou S, Shi X, Zhang Q, Li Y, Wang M Heliyon. 2024; 10(9):e29933.

PMID: 38707417 PMC: 11066311. DOI: 10.1016/j.heliyon.2024.e29933.

Involvement of FAM83 Family Proteins in the Development of Solid Tumors: An Update Review.

Jiang Y, Yu J, Zhu T, Bu J, Hu Y, Liu Y J Cancer. 2023; 14(10):1888-1903.

PMID: 37476189 PMC: 10355199. DOI: 10.7150/jca.83420.

Analysis of a large cohort of pancreatic cancer transcriptomic profiles to reveal the strongest prognostic factors.

Posta M, Gyorffy B Clin Transl Sci. 2023; 16(8):1479-1491.

PMID: 37260110 PMC: 10432876. DOI: 10.1111/cts.13563.

Regulation of early diagnosis and prognostic markers of lung adenocarcinoma in immunity and hypoxia.

Sun K, Zhang Z, Wang D, Huang Y, Zhang J, Lian C Sci Rep. 2023; 13(1):6459.

PMID: 37081097 PMC: 10119119. DOI: 10.1038/s41598-023-33404-8.

References

Kolch W, Pitt A . Functional proteomics to dissect tyrosine kinase signalling pathways in cancer. Nat Rev Cancer. 2010; 10(9):618-29. DOI: 10.1038/nrc2900. View

She Q, Solit D, Basso A, Moasser M . Resistance to gefitinib in PTEN-null HER-overexpressing tumor cells can be overcome through restoration of PTEN function or pharmacologic modulation of constitutive phosphatidylinositol 3'-kinase/Akt pathway signaling. Clin Cancer Res. 2003; 9(12):4340-6. View

Shah N, Nicoll J, Nagar B, Gorre M, Paquette R, Kuriyan J . Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemia. Cancer Cell. 2002; 2(2):117-25. DOI: 10.1016/s1535-6108(02)00096-x. View

Qi X, Wildey G, Howe P . Evidence that Ser87 of BimEL is phosphorylated by Akt and regulates BimEL apoptotic function. J Biol Chem. 2005; 281(2):813-23. DOI: 10.1074/jbc.M505546200. View

Normanno N, De Luca A, Maiello M, Campiglio M, Napolitano M, Mancino M . The MEK/MAPK pathway is involved in the resistance of breast cancer cells to the EGFR tyrosine kinase inhibitor gefitinib. J Cell Physiol. 2006; 207(2):420-7. DOI: 10.1002/jcp.20588. View

Lynch T, Bell D, Sordella R, Gurubhagavatula S, Okimoto R, Brannigan B . Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. N Engl J Med. 2004; 350(21):2129-39. DOI: 10.1056/NEJMoa040938. View

Ley R, Ewings K, Hadfield K, Howes E, Balmanno K, Cook S . Extracellular signal-regulated kinases 1/2 are serum-stimulated "Bim(EL) kinases" that bind to the BH3-only protein Bim(EL) causing its phosphorylation and turnover. J Biol Chem. 2003; 279(10):8837-47. DOI: 10.1074/jbc.M311578200. View

She Q, Solit D, Ye Q, OReilly K, Lobo J, Rosen N . The BAD protein integrates survival signaling by EGFR/MAPK and PI3K/Akt kinase pathways in PTEN-deficient tumor cells. Cancer Cell. 2005; 8(4):287-97. PMC: 3203692. DOI: 10.1016/j.ccr.2005.09.006. View

Ng K, Hillmer A, Chuah C, Juan W, Ko T, Teo A . A common BIM deletion polymorphism mediates intrinsic resistance and inferior responses to tyrosine kinase inhibitors in cancer. Nat Med. 2012; 18(4):521-8. DOI: 10.1038/nm.2713. View

10.

Chapman P, Hauschild A, Robert C, Haanen J, Ascierto P, Larkin J . Improved survival with vemurafenib in melanoma with BRAF V600E mutation. N Engl J Med. 2011; 364(26):2507-16. PMC: 3549296. DOI: 10.1056/NEJMoa1103782. View

11.

Luo J, Solimini N, Elledge S . Principles of cancer therapy: oncogene and non-oncogene addiction. Cell. 2009; 136(5):823-37. PMC: 2894612. DOI: 10.1016/j.cell.2009.02.024. View

12.

Weinstein I, Joe A . Mechanisms of disease: Oncogene addiction--a rationale for molecular targeting in cancer therapy. Nat Clin Pract Oncol. 2006; 3(8):448-57. DOI: 10.1038/ncponc0558. View

13.

Avraham R, Yarden Y . Feedback regulation of EGFR signalling: decision making by early and delayed loops. Nat Rev Mol Cell Biol. 2011; 12(2):104-17. DOI: 10.1038/nrm3048. View

14.

Harada H, Quearry B, Ruiz-Vela A, Korsmeyer S . Survival factor-induced extracellular signal-regulated kinase phosphorylates BIM, inhibiting its association with BAX and proapoptotic activity. Proc Natl Acad Sci U S A. 2004; 101(43):15313-7. PMC: 524459. DOI: 10.1073/pnas.0406837101. View

15.

Ewings K, Hadfield-Moorhouse K, Wiggins C, Wickenden J, Balmanno K, Gilley R . ERK1/2-dependent phosphorylation of BimEL promotes its rapid dissociation from Mcl-1 and Bcl-xL. EMBO J. 2007; 26(12):2856-67. PMC: 1894764. DOI: 10.1038/sj.emboj.7601723. View

16.

Lee S, Meier R, Furuta S, Lenburg M, Kenny P, Xu R . FAM83A confers EGFR-TKI resistance in breast cancer cells and in mice. J Clin Invest. 2012; 122(9):3211-20. PMC: 3428077. DOI: 10.1172/JCI60498. View

17.

Cipriano R, Graham J, Miskimen K, Bryson B, Bruntz R, Scott S . FAM83B mediates EGFR- and RAS-driven oncogenic transformation. J Clin Invest. 2012; 122(9):3197-210. PMC: 3428078. DOI: 10.1172/JCI60517. View